Jasper Therapeutics Files 8-K to Furnish Previously Omitted Exhibits

What Happened
Jasper Therapeutics, Inc. (NASDAQ: JSPR) filed a Form 8-K on October 1, 2026 (Accession No. 0001213900-26-105924) to furnish Exhibits referenced in Item 9.01 — specifically the portions under Items 9.01(a) and 9.01(b) that were not included in the company’s original Form 8-K pursuant to Items 9.01(a)(3) and 9.01(b)(2). This filing supplies the previously omitted financial statement/exhibit materials; it does not report earnings or management changes.

Key Details

• Filed: October 1, 2026; Accession No.: 0001213900-26-105924
• Item addressed: 9.01 (Financial Statements and Exhibits) — subsections .01(a) and .01(b) that were omitted earlier under Items 9.01(a)(3) and 9.01(b)(2)
• Purpose: To furnish the previously omitted exhibits and finalize the administrative disclosure for that earlier Form 8-K
• No new Item-level events (e.g., earnings, executive changes, mergers) were reported in this filing

Why It Matters
This is a technical/corrective filing that completes the company’s disclosure record by supplying the missing exhibits tied to financial statements and related materials. For investors, it means the SEC filing record for Jasper is now more complete and you should review the newly furnished exhibits if you rely on the company’s public filings for financial or legal detail. This filing is procedural and does not itself disclose new operational results or executive actions.